Original Article

Synthesis and evaluation of 2-^{18}F-fluoro-5-iodo-3-[2-(S)-3,4-dehydropyrrolinylmethoxy]pyridine (^{18}F-Niofene) as a potential imaging agent for nicotinic α4β2 receptors

Sharon A Kuruvilla¹, Ansel T Hillmer², Dustin W Wooten², Ashna Patel¹, Bradley T Christian², Jogeshwar Mukherjee¹

¹Preclinical Imaging, Department of Radiological Sciences, University of California, Irvine, CA 92697, USA; ²Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA

Received April 8, 2014; Accepted April 22, 2014; Epub June 7, 2014; Published June 15, 2014

Abstract: Nicotinic α4β2 acetylcholine receptors (nAChRs) have been implicated in various pathophysologies including neurodegenerative diseases. Currently, 2-^{18}F-A85380 (2-FA) and 5-^{123}I-A85380 (5-IA) are used separately in human PET and SPECT studies respectively and require >4-6 hours of scanning. We have developed 2-fluoro-5-iodo-3-[2-(S)-3-dehydropyrrolinylmethoxy]pyridine (niofene) as a potential PET/SPECT imaging agent for nAChRs with an aim to have rapid binding kinetics similar to that of ^{18}F-nifene used in PET studies. Niofene exhibited a 10-fold better in vitro binding affinity in rat brain than that of nicotine. The relative binding of niofene was similar to that of niodene and twice as better as that of nifene. In vitro autoradiography in rat brain slices alongside niodene indicated selective binding of niofene to regions consistent with α4β2 receptor distribution. Niofene, 10 nM, displaced >70% of ^{3}H-cytisine bound to α4β2 receptors in rat brain slices. Radiolabeling of ^{18}F-niofene was achieved in 10-15% radiochemical yield in high specific activities >2 Ci/μmol and showed rapid in vivo kinetics similar to that of ^{18}F-nifene and ^{18}F-nifrolene. In vivo PET in rats showed rapid uptake in the brain and selective localization in receptor regions such as the thalamus (TH). Pseudoequilibrium with ^{18}F-niofene was achieved in 30-40 minutes, which is similar to that of ^{18}F-nifene. Further evaluation of ^{18}F-niofene as a potential PET imaging agent is underway. Future studies will be conducted to radiolabel niofene with iodine-123 for use in SPECT imaging.

Keywords: Nicotine, nifene, niodene, nifrolene, fluorine-18

Introduction

Alterations of α4β2 nicotinic acetylcholine receptors (nAChRs) in the brain have shown some significance in the etiology of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease. More recently, this receptor has been found to be overexpressed in mice models of lung tumors [1]. Efforts on imaging α4β2 receptors using positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are currently underway with 2-^{18}F-A85380 (2-FA) and 5-^{123}I-A85380 (5-IA) used in human studies for PET and SPECT respectively [2-5]. Although successful, 2-FA and 5-IA both require a period >4-6 hours to work, which is not ideal for patient comfort.

We have developed several α4β2 imaging agents in our laboratory of which the leading ones are the following: agonist ^{18}F-nifene (for PET) and putative antagonists ^{123}I-niodene (for SPECT) and ^{18}F-nifrolene (for PET). With a 3,4-dehydroproline ring system, ^{18}F-nifene has shown rapid brain imaging kinetics with a reduced scan time of <1 hour, which is faster than the well-known 2-FA [6]. ^{123}I-Niodene exhibits similar binding behavior as that of nifene, such as its high affinity for α4β2 receptors, and it also incorporates a 3,4-dehydroproline ring system in its structure. This is evident when niodene displaces specifically bound ^{18}F-nifene in rat brain slices at low concentrations [7]. ^{18}F-Nifrolene also has a 3,4-dehydroproline ring system that allows it to have rapid binding kinetics similar to that of ^{18}F-nifene. All
three agents express high in vitro binding affinity for α4β2 receptors in rat brain homogenate using 3H-cytisine, with nifene’s $K_i = 0.50 \text{ nM}$, niodene’s $K_i = 0.27 \text{ nM}$, and nifrolene’s $K_i = 0.36 \text{ nM}$ [8].

Due to the promising characteristics of nifene and niodene, we have decided to combine their molecular structures to develop a hybrid molecule, 2-fluoro-5-iodo-3-[2-(S)-3-dehydropyrrolylmethoxy]pyridine (niofene) as a potential PET/SPECT imaging agent for nAChRs (Figure 1). Our goal with incorporating the 3,4-dehydroproline ring is to have niofene exhibit similar rapid kinetics to that of nifene. The presence of the iodine at the 5-position causes niofene to become more of an antagonist and share similar binding characteristics as nifrolene. Furthermore, the addition of both fluorine and iodine is to allow niofene to be used in either PET or SPECT imaging, depending on the user’s preference in imaging modalities.

We report here the synthesis of niofene, in vitro binding affinity in rat brain homogenate, in vitro autoradiographic studies in rat brain slices, radiosynthesis of $^{18}$F-niofene, and in vivo PET imaging studies in rat.

Materials and methods

General

All chemicals and solvents were of analytical or HPLC grade from Sigma-Aldrich and Fisher Scientific. (S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrrole-1-carboxylate was purchased from Aroma Circle (San Diego, CA, USA) and 2-Bromo-5-iodopyridin-3-ol was purchased from Sigma-Aldrich (St. Louis, MO, USA). 3H-Cytisine (32.7 Ci/mmole specific activity) was purchased from Perkin Elmer Life and Analytical Sciences (Boston, MA, USA). All water was deionized to specific resistance of <18 mΩ cm using a Millipore Milli-Q water purification system. Electrospray mass spectra were obtained on a Model 7250 mass spectrometer (Micromass LCT). Proton NMR spectra were recorded on a Bruker OMEGA 500-MHz spectrometer. Analytical thin layer chromatography (TLC) was carried out on silica-coated plates (Baker-Flex, Phillipsburg, NJ, USA). Chromatographic separations were carried out on preparative TLC (silica gel GF 20_20 cm, 2000 Am thick; Alltech Assocs., Deerfield, IL, USA) or semi-preparative reverse-phase columns using the Gilson high-performance liquid chromatography (HPLC) systems. Tritium was assayed by using a Packard Tri-Carb Liquid scintillation counter with 65% efficiency. High specific activity $^{18}$F-fluoride was produced in the MC-17 cyclotron or the GE cyclotron using oxygen-18 enriched water ($^{18}$O to $^{18}$F using p, n reaction). The high specific activity $^{18}$F-fluoride was used in subsequent reactions which were carried out in automated radiosynthesis units [either a chemistry processing control unit (CPCU) or a nuclear interface fluorine-18 module]. Fluorine-18 radioactivity was counted in a Capintec dose calibrator, whereas low-level counting was carried out in a well counter (Cobra quantum, Packard Instruments, Boston, MA, USA). Rat brain slices were obtained on a Leica 1850 cryotome. Tritiated cytisine autoradiographic studies were carried out by exposing tissue samples on storage phosphor screens. The apposed phosphor screens were read and analyzed by the OptiQuant acquisition and analysis program of the Cyclone Storage Phosphor System (Packard Instruments). All animal studies were approved by the Institutional Animal Care and Use Committee of University of California-Irvine and University of Wisconsin-Madison, Madison, WI.
Chemistry

3-[2-(S)-N-tertbutoxycarbonyl-2-pyrrolinemethoxy]-2-bromo-5-iodopyridine (8): Niofene precursor 8 was produced under Mitsunobu conditions as previously reported (Figure 2) (7). Diisopropyl azodicarboxylate (DIAD; 0.2 mL) was added to a solution of 2-bromo-5-iodopyridin-3-ol (0.16 g, 0.55 mmol), (S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1Hpyrrole-1-carboxylate (0.1 g; 0.50 mmol) and triphenylphosphine (0.19 g) in tetrahydrofuran (THF; 10 mL), stirred under argon and cooled at 0°C. The reaction mixture was allowed to come up to ambient temperature over a period of 2 hours and was stirred overnight. Purification by preparative TLC (1:4 EtOAc in hexane) was employed to yield 3-[2-(S)-N-tertbutoxycarbonyl-2-pyrrolinemethoxy]-2-bromo-5-iodopyridine (8) as an oil with a modest yield of 42%. 1H-NMR (500 MHz, CDCl3) δ ppm: 8.18 (d, 1H, PyH), 7.42 (d, 1H, PyH), 5.91 (m, 2H, olefinic), 4.80 (m, 1H, CH=CH2), 4.35-3.95 (m, 4H, O-CH3, N-CH2), 1.47 (s, 9H, Boc). MS, m/z, 481, 483 (50%, [M+H]+), 503, 505 (100%, [M+Na]+).

2-fluoro-5-ido-3-[2-(S)-3-dehydropyrrolinylmethoxy]pyridine (10a Niofene): In order to prepare 9a, two fluorination methods were carried out as described below under methods A and B.

Method A: 3-[2-(S)-N-tertbutoxycarbonyl-2-pyrrolinemethoxy]-2-bromo-5-iodopyridine, 8 (46 mg; 0.095 mmol) was taken in 2 mL of THF and tetra-n-butylammonium fluoride (TBAF; 1 mL; 1 mmol) in a round-bottom flask. The mixture was refluxed at 75-85°C for 24 hours. Solution was purified by preparative TLC (9:1 dichloromethane (DCM): MeOH). Product yield was 6.9 mg (0.017 mmol; 18% yield).

Method B: 3-[2-(S)-N-tertbutoxycarbonyl-2-pyrrolinemethoxy]-2-bromo-5-iodopyridine, 8 (46 mg; 0.095 mmol) was dissolved in anhydrous acetonitrile. Kryptofix (36.5 mg; 0.10 mmol), potassium fluoride (9 mg; 0.16 mmol), and dimethyl sulfoxide (1 mL) were added to the solution. The flask was heated at 120-125°C oil bath for 5 hours and then dried. The product was extracted from the reaction mixture using DCM (the aqueous layer removed the Kryptofix...
and inorganics). The DCM solution was purified by preparative TLC (9:1 DCM: MeOH) to provide pure 3-[2-(S)-N-tertbutyloxycarbonyl-2-pyrrolinemethoxy]-2-fluoro-5-iodopyridine, 9a (34.6 mg; 0.083 mmol; 87% yield). 1H-NMR (500 MHz, CDCl$_3$) δ ppm: 8.32 (d, 1H, PyH), 7.63 (d, 1H, PyH), 5.88 (m, 2H, olefinic), 4.80 (m, 1H, pyridine), 5.86 (dd, 2H, olefinic), 4.27 (m, 1H, C$_2$), 1.73 (br, 1H, NH). MS, m/z, 443 (90%, [M+Na]$^+$).

Deprotection of the N-tertbutyloxycarbonyl group in 9a using trifluoroacetic acid (TFA) provided niofene 10a in high yields. 3-[2-(S)-N-tertbutyloxycarbonyl-2-pyrrolinemethoxy]-2-fluoro-5-iodopyridine, 9a (3.5 mg; 0.008 mmol) was taken in DCM (1 mL) and TFA was then added to the solution (0.1 mL) and stirred for 1 hour. DCM (3 mL) and saturated sodium bicarbonate (1 mL) was added to the reaction mixture, and the DCM was extracted and dried over magnesium sulfate. A yield of 2.6 mg (0.008 mmol, quantitative yield) of 2-fluoro-5-iodo-3-[2-(S)-3-dehydropyrrolinylmethoxy]pyridine (10a Niofene ) was obtained. 1H-NMR (500 MHz, CDCl$_3$) δ ppm: 8.24 (d, 1H, PyH), 7.54 (d, 1H, PyH), 5.86 (dd, 2H, olefinic), 4.27 (m, 1H, CH-CH$_2$), 3.94-3.75 (m, 4H, O-C$_2$), 1.45 (s, 9H, Boc). MS, m/z, 321 (100%, [M+H]$^+$).

**In vitro binding affinity**

Using previously described procedures, rat brain homogenate assays using 3H-cytisine were carried out to measure binding affinity of the compounds to α4β2 receptors [9]. The cerebrum of male Sprague-Dawley rats was isolated and homogenized using Tekmar tissumizer (15 seconds, half maximum speed) in the incubation buffer 1:100 (wt/vol). The rat brain homogenate was then centrifuged and the supernatant was discarded. The pellet was then resuspended in the same volume of buffer, homogenized, and centrifuged again. The supernatant was then removed and the final pellet was taken up in the incubation buffer described below to a concentration of 120-150 mg/ml of tissue. All binding assays were carried out in duplicate. Binding assays were carried out in 50 mM Tris buffer at pH 7.4 containing 120 mM NaCl, 5 mM KCl, 1 mM MgCl$_2$ and 2.5 mM CaCl$_2$ in the presence of 1 nM 3H-cytisine at 3-5°C for 75 minutes of incubation. The total assay volume was 0.25 mL. Different concentrations of the assay compound, 0.025 mL (nicotine and niofene, range 10$^{-11}$ to 10$^{-4}$ M), were taken in 0.1 mL of buffer along with 0.025 mL of 1 nM 3H-cytisine. Nonspecific binding was measured using 300 μM nicotine. To start the incubation, 0.1 mL of the rat brain homogenate was added into each assay tube. The incubation was terminated by rapid vacuum filtration through Whatman GF/C filter paper (presoaked in 0.1% polyethyleneimine for 60 minutes) using Brandel tissue harvester. The filters were rapidly washed three times with cold buffer, and the filters were suspended in 10 mL of Bio-Safe II scintillation fluid and counted for 10 minutes in the scintillation counter.

**In vitro autoradiographic studies of niofene**

Horizontal brain slices, 10 μm thick from male Sprague-Dawley rats, were preincubated in buffer (50 mmol/L Tris HCl containing 120 mmol/L NaCl, 5 mmol/L KCl, 2.5 mmol/L CaCl$_2$, 1 mmol/L MgCl$_2$, pH 7.4) for 10 min. The preincubation buffer was then discarded and the slices were incubated with 3H-cytisine (2.5 nM, specific activity of 32.7 Ci/mmol) at an ambient temperature for 75 minutes. Binding was measured in the presence of 10 nM and 1 μM of niofene and 10 nM and 300 μM (for nonspecific binding) of nicotine. After incubation, slices were washed twice (1 minute each) with ice-cold Tris buffer, pH 7.4, followed by a quick rinse in cold (0-5°C) deionized water. The slides were then air dried and apposed to phosphor screens and read by the Cyclone Phosphor Imaging System. The amount of bound 3H-cytisine in the autoradiograms was evaluated in various brain regions as digital lights units (DLU/mm$^2$) using the OptiQuant acquisition and analysis program.

**Radiosynthesis**

Synthesis of 18F-niofene was carried out using modifications of our established procedures of 18F-nifene [6]. The radiosynthesis of 18F-niofene was carried out in the automated unit. Starting with 500-600 mCi of 18F and 2 mg of precursor 8, 18F-niofene 10b was obtained. An Alltech C$_{18}$ column (10 μm, 250 x 10 mm$^2$) was used for reverse-phase HPLC purification (60% acetonitrile, 40% water, flowrate 5 mL/min) and specific activity of 18F-niofene was approximately 2000 Ci/mmol. The collected fraction was taken to near dryness in vacuo. The final formulation of 18F-niofene was carried out using...
approximately 2 to 5 mL of saline (0.9% NaCl INJ) followed by filtration through a membrane filter (0.22 μm) into a sterile dose vial for use in the PET studies.

In vivo rat PET imaging

Male Sprague-Dawley rats were fasted 24 hours prior to time of scan. Rats were initially anesthetized using 4.0% isoflurane prior to scanning procedures. The rat was placed on the scanner bed, on a warm-water circulating heating pad, and anesthesia was applied using a nose-cone. A transmission scan was subsequently acquired. Preparation of separate dose injections of $^{18}$F-niofene, $^{18}$F-nifene, and $^{18}$F-nifrolene was as follows: 0.6 ± 0.2 mCi was drawn into a 1 mL syringe and diluted with sterile saline to a final volume of 0.3 mL. The dose was injected into the tail vein of the rat intravenously. Isoflurane was reduced and maintained at 2.5% following the injection. Emission data was collected beginning with bolus injection of radiotracer and was continued for 90-120 minutes after injection. List mode emission data were collected and rebinned using a Fourier Rebinning algorithm. The images were reconstructed using 2 dimensional Filtered Back Projection using a Hanning Filter with a Nyquist cut off at 0.5, and corrected for attenuation using the Co-57 attenuation scan data. Calibration was conducted using a Germanium-68 phantom to Bq/cc units, which was scanned in the Inveon MicroPET and reconstructed under the same parameters as the subjects. Analyses of all data were done using Acquisition Sino-gram Image Processing IDL’s virtual machine (ASIPRO VM).

Results

Chemistry

Mitsunobu coupling reaction of (S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate 6 and 2-bromo-5-iodo-3-hydroxypyridine 7 gave the ether 2-bromo-5-iodo-3-[2-((S)-N-tertbutoxycarbonyl-3-pyrroline)methoxy]pyridine 8 in 42% yield. The exchange of bromide with fluoride using TBAF was carried out in 18% yield, while an alternate method of using Kryptofix and potassium fluoride provided 87% yield of 2-fluoro-5-iodo-3-[2-((S)-N-tertbutoxy carbonyl-3-pyrroline)methoxy]pyridine 9a. De-protection of the BOC group in 9a proceeded efficiently using TFA in quantitative yields to provide 2-fluoro-5-iodo-3-[2-(S)-3-dehydropyrrolinylmethoxy]pyridine (niofene, 10a).

In vitro binding affinity

Binding affinity at the α4β2 receptor subtype in rat brain homogenates was measured using $^3$H-cytisine. In rat brain homogenates, $^3$H-cytisine binds with high affinity ($K_d = 0.59$ nM). The competitive binding assays with $^3$H-cytisine were carried out for two different inhibitors: nicotine and niofene. The binding affinity curves for nicotine and niofene are shown in Figure 3 (average of two measurements for each compound), and the calculated $K_i$ values for these and other compounds are summarized in Table 1. Niofene was found to be slightly higher in affinity at the α4β2 receptor subtype than nicotine. Subnanomolar affinity of niofene results from its structural features resembling that of nifene and niodene [7].

In vitro autoradiographic studies

Competition of unlabeled niofene and niodene with $^3$H-cytisine was carried out in rat brain slices. Thalamus to cerebellum (CB) ratio in the presence of 10 nM niofene was reduced from 11.1 to 2.9, suggesting a >70% decrease and 10 nM of niodene reduced the ratio to 1.7 (>80% decrease) (Figure 4). These results suggest that niofene binds at the same α4β2 receptor sites as $^3$H-cytisine, which reflect the
concentrations of the α4β2 receptors in the various brain regions [10].

Radiosynthesis

Radiosynthesis of 18F-niofene was carried out in two steps. In the first step, the BOC-protected bromo group 8 was reacted by 18F-fluoride (either from an MC-17 Scandotronix cyclotron or RDS 112 cyclotron) by aromatic nucleophilic substitution reaction using Kryptofix and potassium carbonate in DMSO–CH3CN at 120°C for 30 minutes. The bromo-to-fluoride exchange proceeded in good yields of 9b. The mixture was purified by HPLC (C18 Alltech reverse phase column) with a gradient of 0.1% aqueous triethylamine (40%) and acetonitrile (60%) with a flow rate of 5 mL/min. The retention time of 18F-N-BOC-niofene 9b was found to be 19 minutes. The radioactive peak was collected and solvents removed. Deprotection of the N-BOC protecting group was carried out with TFA at 80°C for 30 minutes. The radiosynthesis was accomplished in 2.5 hours with an overall radiochemical yield of 10-15% of 18F-niofene 10b, decay corrected. The specific activity in several runs was estimated to be >2 Ci/μmol.

In vivo rat PET imaging

In vivo PET in rats showed rapid uptake in the brain and selective localization in receptor regions (Figure 5). Uptake of 18F-niofene in the brain reached levels of approximately 1% injected dose/cc. Thalamus exhibited the highest retention as it has a maximum amount of α4β2 receptors. Significant levels of uptake were observed in other regions of the cortex while retention in the cerebellum was lower. Time activity curves of the thalamus and cerebellum

Table 1. Binding Affinity of Compounds at α4β2 nAChR in Rat Brain Tissue

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Compound</th>
<th>Imaging Modality</th>
<th>Radioisotope to be Used</th>
<th>Binding Affinity, K, nM</th>
<th>Relative Affinity to Nicotine</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Nicotine</td>
<td>PET</td>
<td>11C</td>
<td>2.83/30°</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>Nifene</td>
<td>PET</td>
<td>18F</td>
<td>0.50°</td>
<td>5.7</td>
</tr>
<tr>
<td>3</td>
<td>Niodene</td>
<td>SPECT</td>
<td>123I</td>
<td>0.27°</td>
<td>10.5</td>
</tr>
<tr>
<td>4</td>
<td>Nifrolene</td>
<td>PET</td>
<td>18F</td>
<td>0.36°</td>
<td>7.9</td>
</tr>
<tr>
<td>5</td>
<td>Niofene</td>
<td>PET/SPECT</td>
<td>18F/123I</td>
<td>2.90°</td>
<td>10.3</td>
</tr>
</tbody>
</table>

*Binding assay with 3H-cytisine in rat brain homogenates using reported methods [9]; K calculated from IC50 using Cheng-Prusoff equation, K = IC50/(1 + ([3H-cytisine]/Kd)) (1973) and Kd = 0.59 nM for 3H-cytisine. *Taken from our previous works [7, 8]. *K measured using 3H-cytisine in rat brains.

Figure 4. Rat brain 3H-cytisine autoradiography. (A) Scan of rat brain slice; (B) Total binding of 3H-cytisine in different brain regions (AVT, Anterior ventral thalamus; TH, thalamus; SUB, subiculum; FC, frontal cortex; STR, striatum; CB, cerebellum); (C) Binding of 3H-cytisine in the presence of 10 nM niodene; (D) Binding of 3H-cytisine in the presence of 10 nM niofene; (E) Graph of 3H-cytisine binding in brain.
in Figure 5B show initial rapid uptake in various brain regions followed by greater retention in the thalamus compared to the cerebellum. Ratio of uptake for the thalamus against the reference region cerebellum reached a plateau at approximately 30-40 minutes post-injection with a thalamus to cerebellum ratio >2 (Figure 5C).

Discussion

Following similar procedures as nifene, the synthesis of niofene was accomplished in two steps [6]. The first step, involving Mitsunobu coupling, led to a yield that was lower than expected when compared to that of nifene. This decrease in yield may have been due to bulky substituents present in the substituted pyridinol. The second step involved nucleophilic substitution of the 2-bromo with fluoride, which was carried out using two methods: (1) Kryptofix carbonate, and (2) TBAF. Yield was greater and isolation of the product was easier in the Kryptofix method. Similar to deprotection methods of N-BOC nifene, TFA provided deprotection of the N-BOC niofene precursor at high yields.

Niofene was designed on the basis of incorporating the structures of nifene and niodene, which contain a 2-fluorine and 5-iodine respectively. Both nifene and niodene have a higher affinity compared to that of nicotine [7]. It was therefore anticipated that niofene would have a higher affinity compared to that of nicotine since the structure of niofene is the combined structures of nifene and niodene. Our results show that niofene has a higher affinity than that of nicotine (Niofene $K_i = 2.90$ nM; Nicotine $K_i = 30$ nM). Table 1 summarizes the binding affinities of these drugs relative to nicotine for

Figure 5. In vivo PET images of normal rat injected with $^{18}$F-niofene. (A) Sagittal cross-section showing TH and CB; (B) Transverse cross-section showing TH, (C) Time activity curves of TH and CB that show initial rapid uptake in both regions. (D) Using CB as a reference region, plot of TH/CB-1 showing pseudoequilibrium achieved in 30-40 minutes with TH/CB >2.
cross-comparison between studies done at different times. The relative affinities suggest the order of binding affinity to the α4β2 receptors among the derivatives studied thus far is niodene > niofene > nifrolene > nifene > nicotine (all of which contain the dehydroproline ring, with the exception of nicotine).

Binding of 3H-cytisine to α4β2 receptors in rat brain slices was consistent with our observations of 18F-nifene binding and reflected the concentrations of the α4β2 receptors in the various brain regions [10]. The order of 3H-cytisine binding was anterior ventral thalamus (AVT), thalamus, subiculum, frontal cortex, striatum, and cerebellum. Niofene was able to compete with 3H-cytisine labeled α4β2 receptors in rat brain slices effectively. Binding in the thalamus was reduced >70% by niofene while niodene was able to displace slightly greater amounts of 3H-cytisine (refer to Figure 4). These findings suggest that niofene is a selective ligand for α4β2 receptors.

For the radiosynthesis of 18F-niofene, a bromide-for-fluoride substitution was used instead of the nitro-for-fluoride reaction in the radiosynthesis of 18F-nifene [6]. This bromide substitution for the synthesis of 18F-niofene worked equally well with radiochemical yields of >25%, decay-corrected. 18F-niofene was found to be stable for use in in vivo experiments.

18F-Niofene uptake in the rat brain was rapid and was consistent with our previous observations with 18F-nifene [11]. Retention of 18F-
Niofene was evident in the thalamus while it cleared more from the cerebellum. Using the cerebellum as the reference region, pseudo-equilibrium was achieved in 30-40 minutes (similar to that of $^{18}$F-nifene) with TH/CB >2. Consistent with the lower affinity of niofene compared to that of nifene, the binding kinetics of $^{18}$F-nifene showed greater retention in the thalamus compared to that of niofene, thus resulting in slightly greater TH/CB ratios (Figure 6). This is also evident in the sagittal and transverse images of the rat brain in Figure 6A and 6B. Maximum binding was found in the thalamus while moderate binding is seen in the cortex and minimal binding in the cerebellum. Time activity curves for thalamus and cerebellum show $^{18}$F-nifene peaks early into the scan (Figure 6B) and nonspecific binding in the cerebellum cleared rapidly. Thalamus to cerebellum ratios were >3 (Figure 6C).

Based on the structures of niofene and nifene, the former is expected to be an antagonist while the latter is an agonist. It is possible that this difference between the two agents play a factor in their binding kinetics. Therefore, we have also compared the behavior of niofene with our previously reported putative antagonist, nifrolene, shown in Figure 7. Sagittal brain sections also reveal binding in the thalamus while very little binding was present in the cerebellum (Figure 7A). Some extracranial activity was also observed. Time activity curves of the thalamus and cerebellum in Figure 7C show initial rapid uptake in brain regions followed by greater retention in the thalamus compared to the cerebellum. Ratio of uptake for the thalam-
mus against the reference region cerebellum reached a plateau at approximately 60 minutes post-injection. Thalamus to cerebellum ratio was found to be >4 (Figure 7D).

As can be seen in the time activity curves, retention of nifrofene was greater in the thalamus compared to that of both niofene and nifene. It is therefore likely that the binding kinetics of the three related dehydroproline derivatives may be dictated by their binding affinities to the α4β2 receptors.

The presence of a substituent at the 5-position in this class of compounds changes an agonist to an antagonist [12]. Therefore, niofene—which contains an iodine-and nifrofene—which contains a fluoropropyl group—are rendered as antagonists [8]. However, with our preliminary results for niofene reported here, it appears that the nature of the substituent at the 5-position may dictate in vivo kinetics. This may be due to the large spherical iodine atom in niofene versus the carbon chain in the fluoropropyl group in nifrofene. This aspect warrants further investigation.

When radiolabeled with iodine-123, 123I-niofene may have similar in vivo kinetics like that of 18F-nifene and is likely to have faster kinetics compared to that of 5-123I-IA, a SPECT imaging agent currently used in human studies, which requires long imaging times (>4 to 6 hours) [13].

Conclusion

The goal of this study was to combine the molecular structures of two imaging agents previously developed in our lab, nifene and niofene. This was done in order to produce a novel imaging agent, niofene, which has potential use in both PET and SPECT studies whilst exhibiting similar binding kinetics as those of nifene and niodene. Our preliminary studies were focused on niofene’s characteristics and its use solely in PET applications after being radiolabeled with fluorine-18. Results from this study have suggested that niofene is a selective ligand for α4β2 receptors and uptake of 18F-niofene in rat brain was consistent with our previous observations with 18F-nifene. Further investigation will be done to study niofene’s potential use in SPECT applications once radiolabeled with iodine-123.

Acknowledgements

This research was financially supported by a grant from National Institutes of Health, R01 AG 029479. We would like to thank Dr. Todd E. Barnhart and Christopher Liang for technical assistance. We thank Mr. Said Shokair at the Undergraduate Research Opportunities Program (UROP) of the University of California-Irvine for summer support (SAK) through the ID-SURE program.

Disclosure of conflict of interest

The authors have no conflict of interest.

Address correspondence to: Dr. Jogeshwar Mukherjee, B138 Medical Sciences, University of California-Irvine, Irvine, CA 92697, USA. Tel: 949-824-3568; Fax: 949-824-2344; E-mail: j.mukherjee@uci.edu

References


